These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 28522693)

  • 1. Histone H3.3K27M Represses
    Cordero FJ; Huang Z; Grenier C; He X; Hu G; McLendon RE; Murphy SK; Hashizume R; Becher OJ
    Mol Cancer Res; 2017 Sep; 15(9):1243-1254. PubMed ID: 28522693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.
    Fang D; Gan H; Cheng L; Lee JH; Zhou H; Sarkaria JN; Daniels DJ; Zhang Z
    Elife; 2018 Jun; 7():. PubMed ID: 29932419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma.
    Bhattarai S; Hakkim FL; Day CA; Grigore F; Langfald A; Entin I; Hinchcliffe EH; Robinson JP
    bioRxiv; 2024 May; ():. PubMed ID: 38798502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
    Chan KM; Fang D; Gan H; Hashizume R; Yu C; Schroeder M; Gupta N; Mueller S; James CD; Jenkins R; Sarkaria J; Zhang Z
    Genes Dev; 2013 May; 27(9):985-90. PubMed ID: 23603901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells.
    Misuraca KL; Hu G; Barton KL; Chung A; Becher OJ
    Neoplasia; 2016 Jan; 18(1):60-70. PubMed ID: 26806352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.
    Lewis NA; Klein RH; Kelly C; Yee J; Knoepfler PS
    Epigenetics Chromatin; 2022 May; 15(1):18. PubMed ID: 35590427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
    Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
    Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
    An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
    J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
    Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
    J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
    Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
    Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation.
    Tatavosian R; Duc HN; Huynh TN; Fang D; Schmitt B; Shi X; Deng Y; Phiel C; Yao T; Zhang Z; Wang H; Ren X
    Nat Commun; 2018 May; 9(1):2080. PubMed ID: 29802243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
    Chan KM; Han J; Fang D; Gan H; Zhang Z
    Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.
    Pajovic S; Siddaway R; Bridge T; Sheth J; Rakopoulos P; Kim B; Ryall S; Agnihotri S; Phillips L; Yu M; Li C; Milos S; Patel P; Srikanthan D; Huang A; Hawkins C
    Nat Commun; 2020 Dec; 11(1):6216. PubMed ID: 33277484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
    Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
    Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.
    Larson JD; Kasper LH; Paugh BS; Jin H; Wu G; Kwon CH; Fan Y; Shaw TI; Silveira AB; Qu C; Xu R; Zhu X; Zhang J; Russell HR; Peters JL; Finkelstein D; Xu B; Lin T; Tinkle CL; Patay Z; Onar-Thomas A; Pounds SB; McKinnon PJ; Ellison DW; Zhang J; Baker SJ
    Cancer Cell; 2019 Jan; 35(1):140-155.e7. PubMed ID: 30595505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
    Halvorson KG; Barton KL; Schroeder K; Misuraca KL; Hoeman C; Chung A; Crabtree DM; Cordero FJ; Singh R; Spasojevic I; Berlow N; Pal R; Becher OJ
    PLoS One; 2015; 10(3):e0118926. PubMed ID: 25748921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.